the published work on Lyme arthritis in the Federal Republic of Germany I would like to comment on the prevalence of arthritis in patients with Lyme borreliosis and on the clinical characteristics of Lyme arthritis.
In the description of our first 10 patients with Lyme arthritis we already appreciated that the widely held opinion of a different clinical spectrum of Lyme borreliosis in North America and in Europe concerning the prevalence of arthritis might merely reflect the lack of awareness of Lyme arthritis in Europe.2 Our patients with typical histories of early Lyme borreliosis had experienced an odyssey of diagnostic and therapeutic procedures before the diagnosis was considered and confirmed by serological tests. The analysis of a larger number of patients with Lyme borreliosis seen in our general medicine outpatient department then suggested that earlier statements on the relative frequency of the various disease manifestations had been biased by selections of patients from different medical specialties.3 ' In 79 patients arthritis was the most frequent manifestation of the disease (n=50), followed by erythema chronicum migrans (n=32), neurological abnormalities (n= 15), acrodermatitis chronica atrophicans (n=11), and carditis (n=1). Natural killer cell function in ankylosing spondylitis SIR, Natural killer (NK) function has been assessed in several studies in rheumatoid arthritis,' but rarely in ankylosing spondylitis (AS). Recently, many reports have argued for the responsibility of bacterial agents in the development of AS. Anomalies of the immune response against bacterial antigens could favour the occurrence and development of AS. 2 The purpose of this study was to evaluate NK function in patients with AS.
NK cells, in addition to their role in immunological antitumoral surveillance,3 appear to be implicated in anti-infectious and antibacterial defences. This is illustrated by the Chediak-Higashi syndrome, characterised by functional deficiencies of NK activity with a normal number of NK cells, and the occurrence of severe bacterial infections. 4 5 Twenty eight patients (23 male, five female) with definite AS were investigated: mean age 39-5 (SD 5-2) years, 21-were HLA-B27 positive, and 17 were receiving non-steroidal anti-inflammatory drugs (NSAIDs) at the time of investigation. Duration of the disease was less than five years in nine cases and more than 10 years in 12 (mean (SD) 9-4 (2-8) years).
Lymphomonocytes were isolated from peripheral venous blood using a Ficoll-Hypaque density centrifugation gradient. We found no difference in NK cell activity either between patients with AS and controls (as in previous research with a 5"Cr release assay9"'), or between B27 positive and B27 negative patients with AS. Similarly, we found no statistical difference in the number of Leu-7 bearing cells between B27 positive and B27 negative patients with AS. Thus this study provides no evidence for NK function control by the B27 gene.
Moreover, no correlation was found between NK activity and any of the other parameters investigated (ESR, 02 microglobulin, IgA, Leu-7, OKT3, OKT4, OKT8, T4/T8 ratio).
NK activity was significantly decreased (p=0006), however, in patients with AS receiving NSAID treatment compared with non-treated patients. As has been shown in vitro'2 and in vivo'l'5 NSAIDs tend to enhance NK cell activity. Thus the decrease observed in this study could be due to activity of the disease itself rather than to a direct effect of NSAIDs upon cell activity. This has already been suggested by Vinje et al, who found a negative correlation between NK activity and C reactive protein. " Such a reduction in NK activity could be either evidence of an inflammatory reaction leading to hyperproduction of prostaglandins (that decrease NK activity) or, alternatively, a pathogenetic factor contributing to persistence of bacterial antigens according to the current hypothesis of the aetiology of the disease. 
